Nutra Pharma Reports 96% Revenue Growth but Increased Net Loss in Q1 2025

Nutra Pharma Corp, along with its subsidiary ReceptoPharm, reported its financial results for the first quarter ending March 31, 2025, revealing a significant increase in net sales compared to the same period in the previous year. The company generated net sales of $73,974,000, a 96% increase from $37,732,000 in the first quarter of 2024. Despite this growth in revenue, Nutra Pharma reported a net loss of $1,404,923, which is a substantial increase from the net loss of $426,934 recorded in the prior year. The increase in losses was attributed to higher operating expenses and significant changes in the fair value of convertible notes and derivatives.

The company's total current assets rose to $552,117,000 as of March 31, 2025, up from $374,837,000 at the end of 2024. This increase was primarily driven by a rise in accounts receivable and other receivables. However, total liabilities also increased, reaching $16,988,016, compared to $15,407,409 at the end of the previous fiscal year. The stockholders' deficit widened to $16,212,837 from $14,807,914, reflecting the ongoing challenges in achieving profitability and managing debt.

Operationally, Nutra Pharma continues to focus on its product lines, which include pain relief medications such as Cobroxin and Nyloxin. The company has also expanded its product offerings to include various formulations aimed at different consumer segments, including pets and equine products. The filing indicates that sales to related parties accounted for approximately 33% of total revenues in the first quarter of 2025, down from 48% in the same period last year, suggesting a diversification in its customer base.

Looking ahead, Nutra Pharma faces significant challenges, including a working capital deficit of $16,296,563 and an accumulated deficit of $77,636,060. The company has expressed substantial doubt regarding its ability to continue as a going concern without securing additional financing. Management indicated that it will continue to rely on debt and equity funding to support operations, but the current market conditions and the company's stock being listed on the OTC Market Group's Expert Market limit its ability to raise capital effectively. The outlook remains uncertain as Nutra Pharma aims to increase sales and achieve profitability to sustain its operations in the competitive biotechnology market.